FDA Approves Actemra (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
Links shared publicly online about this topic.
- 355total visits
FDA Approves Actemra (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
View full resource at drugs.com
Tags: Arthritis, Rheumatoid Arthritis Medication, Juvenile Rheumatoid Arthritis, Drug, Children's Health, FDA, Actemra
Most Recently Shared on April 19, 2011 at 4:12 am By:
FDA Approves Actemra (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA): SOU... http://bit.ly/h7x9uE #drug
Jab that ends the agony of childhood arthritis: New NHS treatment brings relief to nine in ten young patients | Mail Online
dailymail.co.uk — “NICE has approved RoActemra (tocilizumab) to treat systemic juvenile idiopathic arthritis (sJIA) which is currently incurable.” View full resource at dailymail.co.uk
Most Recently Shared on February 4, 2012 at 11:25 pm By:
Jab that ends the agony of childhood arthritis: New NHS treatment brings ... http://t.co/UNyqvFt2
ACTEMRA (tocilizumab) | Rheumatoid Arthritis Treatment
actemra.com — “Find information about ACTEMRA, an FDA-approved treatment for rheumatoid arthritis. ACTEMRA is a prescription medicine called an interleukin-6 (IL-6) receptor inhibitor. ACTEMRA is used to treat adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a Tumor Necrosis Factor (TNF) antagonist has been used and did not work well. ACTEMRA is used to treat people with active systemic juvenile idiopathic arthritis (SJIA) 2 years of age and older. So” View full resource at actemra.com
Most Recently Shared on January 20, 2012 at 3:35 pm By:
FDA Approves Actemra (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
drugs.com — “Actemra (tocilizumab) is used to treat Rheumatoid Arthritis and Systemic Juvenile Idiopathic Arthritis . Includes Actemra side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on April 19, 2011 at 3:15 am By:
FDA Approves Actemra for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) - http://bit.ly/gKMQJR
Actemra Gains Approval for Systemic Juvenile Idiopathic Arthritis - ONA
oncologynurseadvisor.com — “The FDA has approved Actemra (tocilizumab; Genentech), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis (SJIA), or Still--™s disease, in children 2 years.” View full resource at oncologynurseadvisor.com
Most Recently Shared on April 18, 2011 at 4:12 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Actemra Gains Approval for Systemic Juvenile Idiopathic Arthritis http://goo.gl/fb/Fz9Ea
Actemra Gains Approval for Systemic Juvenile Idiopathic Arthritis - MPR
empr.com — “The FDA has approved Actemra (tocilizumab; Genentech), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis (SJIA), or Still--™s disease, in children 2 years.” View full resource at empr.com
Most Recently Shared on April 18, 2011 at 4:11 pm By:
MPR News: Actemra Gains Approval for Systemic Juvenile Idiopathic Arthritis: The FDA has approved Actemra (tocil... http://bit.ly/erCY89
Advertisement
